Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit to Provide SpliceArray Content on Affymetrix GeneChip Platform

NEW YORK, Oct. 17 (GenomeWeb News) - ExonHit Therapeutics said today that it has inked a supply and service provider agreement to join its SpliceArray alternative RNA splicing technologies with Affymetrix's GeneChip microarray platform.


The first GeneChip arrays featuring ExonHit's technology are expected to be available on the Affymetrix platform by year end. These will include GPCR, ion channel, nuclear receptor, apoptosis, and the cytokine gene families, ExonHit said.


Customers will be able to access ExonHit's microarray content through a licensing agreement with the company. GeneChip arrays with the alternative RNA splicing technologies can then be purchased directly from Affymetrix.


"License fees will be directly proportional to the number of SpliceArrays purchased, with significant discounts for volume commitments and no reach-through rights," ExonHit said. "Alternatively, ExonHit ... can run and analyze customers' samples through its SpliceArray service."

Additional terms of the deal were not disclosed.


The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.